November 2015 in “Ankara Medical Journal” Weekly 5 mg folate is enough to prevent methotrexate toxicity in rheumatoid arthritis patients.
June 2023 in “Fundamental & clinical pharmacology” JAK inhibitors help treat some diseases but may increase risks of blood clots and cancer in certain patients.
September 2025 in “Tạp chí Da liễu học Việt Nam” 2.5 mg/mL TAC is as effective and safe as 5 mg/mL, but 5 mg/mL may improve hair regrowth and density more.
2 citations
,
May 2024 in “International Journal of Dermatology”
1 citations
,
November 2001 in “British Journal of Dermatology” Oral cyclosporin doesn't stop hair loss.
2 citations
,
January 2022 in “BioMed Research International” Gujian oral liquid reduces osteoarthritis symptoms by targeting inflammation.
May 2024 in “Reactions weekly”
January 2025 in “The Egyptian Journal of Hospital Medicine” Baricitinib is effective and safe for treating localized vitiligo, alone or with topical tacrolimus.
1 citations
,
February 2025 in “Toxicology in Vitro” Diphlorethohydroxycarmalol may help treat hair loss better than current medications.
February 2006 in “Journal of The American Academy of Dermatology” Terbinafine is more effective than itraconazole for toenail fungus, especially in older patients, and debridement improves its effectiveness.
38 citations
,
June 2015 in “PubMed” Calcipotriol cream can effectively and safely treat mild-to-moderate patchy hair loss.
October 2023 in “The Open Dermatology Journal” Baricitinib is effective for severe alopecia areata with manageable side effects, mainly upper respiratory infections.
1 citations
,
January 2024 in “Journal of Cutaneous and Aesthetic Surgery” Fractional CO2 laser with topical triamcinolone is more effective and safer for treating alopecia areata than intralesional triamcinolone.
1 citations
,
September 2023 in “Journal of the American Academy of Dermatology” Mini pulse corticosteroid therapy with oral dexamethasone is effective and has fewer side effects for treating extensive alopecia areata.
January 2023 in “Open veterinary journal” A cat developed skin problems from a certain brand of injected water pills, which went away after switching brands.
1 citations
,
November 2025 in “International Journal of Clinical Pharmacy” Cladribine has known risks and potential new safety concerns, requiring careful monitoring.
1 citations
,
July 2024 in “Journal of Investigative Dermatology” TAK-279 effectively reduces psoriasis symptoms and is safe.
14 citations
,
October 1977 in “The Lancet” December 2025 in “Zenodo (CERN European Organization for Nuclear Research)” December 2025 in “Zenodo (CERN European Organization for Nuclear Research)”
September 2022 in “XXXIX Congresso Brasileiro de Reumatologia” Tofacitinib may effectively treat skin symptoms in difficult cases of dermatomyositis.
18 citations
,
July 2018 in “Journal of Cosmetic Dermatology” Calcipotriol plus betamethasone with microneedling works better than tacrolimus for treating vitiligo.
1 citations
,
July 2021 in “Current nanomedicine” The new gel formulation for Acitretin improves topical delivery and reduces oral toxicity.
September 2018 in “Practical diabetes” Sodium valproate is not recommended as a first-line treatment for neuropathy but may be used in resistant cases.
8 citations
,
October 2022 in “Dermatology practical & conceptual” Tofacitinib and ruxolitinib are effective and safe for treating various autoimmune skin and joint disorders.
20 citations
,
March 2017 in “Arthritis research & therapy” Social media can help compare the effectiveness and safety of new arthritis medications.
1 citations
,
December 2024 in “Archives of Iranian Medicine” Tofacitinib may help treat Lichen Planopilaris, but more research is needed.
7 citations
,
January 2025 in “Journal of Medicinal Chemistry” New itaconate prodrugs improve its absorption and effectiveness for treating inflammation.
49 citations
,
November 2013 in “JAMA dermatology” Clobetasol propionate, 0.05%, is more effective and safe for treating childhood alopecia areata than hydrocortisone, 1%.
15 citations
,
August 2002 in “British Journal of Ophthalmology” Intralesional cidofovir might be a viable alternative treatment for certain conditions.